DMD and Duchenne muscular dystrophy: More recently, researchers are trying to useCRISPR/Cas9 genome editing system to remove mutated exons from the DMD gene.85, 86 This method uses small guide RNAs coupled with target‐specific double‐strand DNA endonuclease making possible targeted gene disruption, replacement or modification.87 The CRISPR/Cas9 approach has shown ability to rescue dystrophin expression in DMD patient‐derived iPSC in vitro, and in muscles of experimental models of DMD in vivo.88 Similar to AON, application of CRISPR/Cas9 method to DMD patients requires a personalized setting depending on the specific mutation.